In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

David M Livermore; Marina Warner; Shazad Mushtaq; Sarah North; Neil Woodford

doi:10.1128/AAC.01347-06

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

David M Livermore, Marina Warner, Shazad Mushtaq, Sarah North, Neil Woodford

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 microg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 microg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 microg/ml, versus linezolid MICs of 8 to 64 microg/ml; actual values reflected the proportion of gene copies mutated.

Original language	English
Pages (from-to)	1112-4
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	51
Issue number	3
DOIs	https://doi.org/10.1128/AAC.01347-06
Publication status	Published - Mar 2007

Keywords

Acetamides
Anti-Bacterial Agents
Drug Resistance, Bacterial
Enterococcus faecalis
Enterococcus faecium
Methicillin Resistance
Microbial Sensitivity Tests
Mutation
Oxazolidinones
Polymorphism, Restriction Fragment Length
Reverse Transcriptase Polymerase Chain Reaction
Staphylococcus aureus

Access to Document

10.1128/AAC.01347-06

Cite this

@article{d782eab57db14c3ebbf3648fe4e0113b,

title = "In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci",

abstract = "RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 microg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 microg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 microg/ml, versus linezolid MICs of 8 to 64 microg/ml; actual values reflected the proportion of gene copies mutated.",

keywords = "Acetamides, Anti-Bacterial Agents, Drug Resistance, Bacterial, Enterococcus faecalis, Enterococcus faecium, Methicillin Resistance, Microbial Sensitivity Tests, Mutation, Oxazolidinones, Polymorphism, Restriction Fragment Length, Reverse Transcriptase Polymerase Chain Reaction, Staphylococcus aureus",

author = "Livermore, {David M} and Marina Warner and Shazad Mushtaq and Sarah North and Neil Woodford",

year = "2007",

month = mar,

doi = "10.1128/AAC.01347-06",

language = "English",

volume = "51",

pages = "1112--4",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

TY - JOUR

T1 - In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

AU - Livermore, David M

AU - Warner, Marina

AU - Mushtaq, Shazad

AU - North, Sarah

AU - Woodford, Neil

PY - 2007/3

Y1 - 2007/3

N2 - RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 microg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 microg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 microg/ml, versus linezolid MICs of 8 to 64 microg/ml; actual values reflected the proportion of gene copies mutated.

AB - RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 microg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 microg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 microg/ml, versus linezolid MICs of 8 to 64 microg/ml; actual values reflected the proportion of gene copies mutated.

KW - Acetamides

KW - Anti-Bacterial Agents

KW - Drug Resistance, Bacterial

KW - Enterococcus faecalis

KW - Enterococcus faecium

KW - Methicillin Resistance

KW - Microbial Sensitivity Tests

KW - Mutation

KW - Oxazolidinones

KW - Polymorphism, Restriction Fragment Length

KW - Reverse Transcriptase Polymerase Chain Reaction

KW - Staphylococcus aureus

U2 - 10.1128/AAC.01347-06

DO - 10.1128/AAC.01347-06

M3 - Article

C2 - 17210773

VL - 51

SP - 1112

EP - 1114

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 3

ER -